Just $7/month gets you a limited edition KaiPA pint glass. Plus bragging rights that you support independent journalism.
Donate today to get yours!
TEXT OF INTERVIEW
Steve Chiotakis: Researchers today are calling it a world first. It’s an experimental vaccine that’s cut the risk of HIV infection by nearly a third. The trial involved a combination of two vaccines —
one American, the other French. Marketplace’s European Correspondent Stephen Beard is with us now. Hi, Stephen.
Stephen Beard: Good morning, Steve.
Chiotakis: So tell us more about the study.
Beard: Sponsored by the U.S. Army, it cost $100 million to carry out. It involved 16,000 volunteers in Thailand. Half took a placebo. The other half received a sort of vaccine coctail, a combination of two vaccines which have separately proved inneffective. Together, they apparently cut the rate of HIV infection by a third. Now not of itself sufficient to make a proper vaccine, but this is the first time in 25 years of research that anything has proved remotely effective as a vaccine against AIDS, so it is being hailed as a breakthrough.
Chiotakis: Yeah, and I would imagine, Stephen, there are many questions at this point as to whether it can be produced commercially, right?
Beard: Oh, very much so. I spoke to a professor of immunology in London this morning, who said that scientifically this is exciting, but at this stage, it may only be a vaccine that works against HIV strains prevalent in Thailand, which might limit its relavance elsewhere. And she said we really don’t know enough about how this vaccine might work to know whether it is going to lead onto a global vaccine. We’ll have to wait til next month for a major meeting in Paris, when the full results of this trial will be made public.
Chiotakis: So much to explore going forward. Our Marketplace European Correspondent Stephen Beard joining us this morning. Stephen, thanks.
Beard: OK, Steve.
As a nonprofit news organization, our future depends on listeners like you who believe in the power of public service journalism.
Your investment in Marketplace helps us remain paywall-free and ensures everyone has access to trustworthy, unbiased news and information, regardless of their ability to pay.
Donate today — in any amount — to become a Marketplace Investor. Now more than ever, your commitment makes a difference.